FDA Announces Final Guidance to Address Sepsis Risk in Donor Eligibility for Human Cells and Tissues
January 07, 2025
January 07, 2025
WASHINGTON, Jan. 7 (TNSFR) -- The Food and Drug Administration (FDA) has announced the immediate availability of a final guidance aimed at reducing the risk of transmission of disease agents associated with sepsis by human cells, tissues, and cellular and tissue-based products (HCT/Ps). The guidance provides recommendations for establishments involved in donor eligibility determinations, focusing on the clinical screening of potential donors for signs of sepsis.
The FDA highlights . . .
The FDA highlights . . .